Gelteq GELS

NASDAQ GELS
$0.56 +0.02 (+4.59%)
At close: Aug 19, 2026 · 2:54 PM UTC
Financial Ratios
Market Cap5.63 Mn
Div. Yield0.00
Total Debt (Qtr)3.35 Mn
Add ratio to table…

About

Gelteq Ltd is a clinical and science‑based company that develops and commercializes white label gel‑based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm produces edible gels that serve as dosage forms, focusing on five verticals—pets, sports, pharmaceutical, over‑the‑counter and nutraceutical—using patent‑pending multi‑ingredient formulations. Gelteq’s business model centers on out‑licensing its technology…

Read more ↓
Sectors: Healthcare · Consumer Staples Sector rationale The company's primary focus is on clinical and science-based drug delivery solutions, specifically developing gel dosage forms for prescription drugs and pursuing FDA approval for therapeutics, which falls under Healthcare. A secondary sector of Consumer Staples is justified because the company also manufactures and licenses gel-based supplements for pets and human nutraceuticals sold to third-party brands. Industries: Contract Manufacturing Healthcare Primary Gelteq operates as a white-label manufacturer and licensor of gel-based delivery solutions for prescription drugs and therapeutics. Its revenue model is based on manufacturing products for third-party clients and receiving milestone fees and licensing payments for its drug delivery technology. Animal Health Healthcare Secondary The company has a dedicated Pet gels segment that develops gel-based supplements for companion animals targeting joint health, diabetes, and digestion. Personal Care Products Consumer Staples Secondary Gelteq develops and manufactures over-the-counter (OTC) gels and nutraceuticals for human nutrition and sports performance, selling these to nutraceutical firms and sports teams. Classified using BQ-MICS CIK: 0001920092

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 HLN Haleon plc 86.50 Bn80.681.67-5.81 Bn
2 TEVA Teva Pharmaceutical Industries Ltd 42.71 Bn61.362.4716.59 Bn
3 ZTS Zoetis Inc. 30.86 Bn11.803.249.05 Bn
4 TAK Takeda Pharmaceutical Co Ltd 28.50 Bn49.630.6131.47 Bn
5 UTHR UNITED THERAPEUTICS Corp 22.06 Bn16.836.99-
6 VTRS Viatris Inc 18.84 Bn-45.871.2813.35 Bn
7 NBIX Neurocrine Biosciences Inc 15.55 Bn22.034.61-
8 VREOF Vireo Growth Inc. 11.86 Bn-238.0033.850.20 Bn